CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 34 enrolled
Drug / intervention
ATI-50002 topical solutiondrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03468855
NCT03468855Phase 2Completed
CompareCT.gov

An Open-Label Pilot Study of the Safety, Tolerability and Efficacy of ATI-50002 Topical Solution Administered Twice-Daily in Adult Subjects With Non-Segmental Facial Vitiligo

Aclaris Therapeutics, Inc.·interventional·Posted Mar 19, 2018·Updated Nov 30, 2020

In Brief

A Phase 2 clinical trial evaluating ATI-50002 topical solution for Vitiligo. Completed, enrolled 34 participants across 5 sites.

Detailed Summary

The main objective of this study is to assess the safety, tolerability and efficacy of ATI-50002 Topical Solution, 0.46% in subjects with non-segmental facial vitiligo.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsVitiligo
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedMar 19, 2018
Enrollment StartMar 19, 2018
Primary CompletionOct 16, 2019
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 8.3 years ago

Interventions

ATI-50002 topical solutiondrug

Topical Solution administered twice daily